Sign Up
OverviewAPI
Nexcella and Immix Biopharma both present updated data from their Phase 1b/2 clinical trials of BCMA-targeted CAR-T cell therapies, NXC-201, at the 20th International Myeloma Society Annual Meeting. NXC-201 shows promising results in multiple myeloma, with 72% overall response rate. Both companies plan to submit data to the FDA for multiple myeloma and AL amyloidosis once 100-30 patients are treated. Nexcella also completes its 2nd engineering batch of NXC-201 at its U.S. manufacturing site, aiming to expand clinical trial to the United States.

Ask a question